Artelo Biosciences (ARTL) Non Operating Income (2017 - 2025)
Artelo Biosciences (ARTL) posted quarterly Non Operating Income of -$1.4 million for Q4 2025, down 4158.82% year-over-year from $34000.0 in Q4 2024, and down 4351.61% quarter-over-quarter from -$31000.0 in Q3 2025.
Artelo Biosciences (ARTL) Non Operating Income (2017 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Non Operating Income for 7 consecutive years, with -$1.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income fell 4158.82% year-over-year to -$1.4 million; the TTM figure through Dec 2025 stood at -$1.5 million (down 623.05% YoY), while the FY2025 annual figure was -$1.5 million, down 623.05% from the prior year.
- Non Operating Income declined to -$1.4 million in Q4 2025 per ARTL's latest filing, from -$31000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $185000.0 in Q2 2023 and bottomed at -$1.4 million in Q4 2025.
- Historically, Non Operating Income has averaged -$20235.3 across 5 years, with a median of $63000.0 in 2024.
- Annual changes were most pronounced in 2023 — Non Operating Income soared 752.63% — and 2025, when it tumbled 4158.82%.
- Artelo Biosciences' Non Operating Income stood at $4000.0 in 2021, then surged by 3325.0% to $137000.0 in 2022, then grew by 21.9% to $167000.0 in 2023, then tumbled by 79.64% to $34000.0 in 2024, then sank by 4158.82% to -$1.4 million in 2025.
- Business Quant data shows ARTL's Non Operating Income at -$1.4 million in Q4 2025, -$31000.0 in Q3 2025, and -$71000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Artelo Biosciences | 111,698.23 | -488,301.77 | - | -1.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.38 Mn |
| Sep 30, 2025 | -31,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2024 | 63,000.00 |
| Jun 30, 2024 | 79,000.00 |
| Mar 31, 2024 | 106,000.00 |
| Dec 31, 2023 | 167,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Jun 30, 2023 | 185,000.00 |
| Mar 31, 2023 | 124,000.00 |
| Dec 31, 2022 | 137,000.00 |
| Sep 30, 2022 | 64,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Nov 30, 2021 | 4,000.00 |
| Nov 30, 2020 | 1,000.00 |
| Aug 31, 2017 | -177.00 |
| May 31, 2017 | -907.00 |